Morphosys Group Ag Anticipates Close Of Proposed Acquisition By Novartis In H1 2024, Submit A New Drug Application For Pelabresib In Combination With Ruxolitinib In Myelofibrosis To FDA And Marketing Authorization Application To European Medicines Agency In H2 2024
Morphosys Group Ag预计将在2024年上半年完成诺华的拟议收购,向美国食品药品管理局提交Pelabresib与鲁索利替尼联合治疗骨髓纤维化的新药申请,并于2024年下半年向欧洲药品管理局提交上市许可申请